Please login to the form below
Shingrix
This page shows the latest Shingrix news and features for those working in and with pharma, biotech and healthcare.
GSK considers more divestments to help R&D push
Looking at the fourth quarter numbers, pharma sales slumped 5% to £4.6bn, but there was an encouraging 18% gain for vaccines to £1.74bn thanks to strong growth for Shingrix,
Latest news
-
GSK boosts outlook thanks to strong respiratory and vaccine sales
Key Q3 drivers include Shingrix vaccine and asthma drug Nucala. GlaxoSmithKline has raised its profit forecast for the second consecutive quarter thanks to the strong sales of its shingles vaccine Shingrix ... Also bringing the forecast up is GSK’s
-
Shingrix lifts GSK in Q1, but two more vaccines are culled
The decision to drop the two vaccines came as another of GSK’s vaccines – Shingrix for shingles – saw its sales rocket in the first three months of the year, reaching £357m ( ... Shingrix’ performance helped GSK’s vaccine unit to a 23% sales
-
GSK upbeat on its return to oncology market
Nevertheless, there is expected to be strong performances from its Shingrix vaccine and next-generation respiratory drug Ellipta, which have both been the focus of GSK’s new drive towards commercial
-
Is GSK planning to exit the respiratory business?
Meanwhile, vaccines grew 12% to £1.92bn led by new shingles vaccine Shingrix which contributed $286m in the quarter.
-
GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing
shingles vaccine Shingrix and HIV treatment Juluca.
More from news
Approximately 9 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
contain the adjuvant QS-21 Stimulon. In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA. GSK's malarial vaccine, Mosquirix which also contains
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
